Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Full-Length Open Reading Frame Amplification of Hepatitis C Virus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. In Vitro Neutralization Assay Using Cultured Hepatitis C Virus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Imaging N-Acyl Homoserine Lactone Quorum Sensing In Vivo

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. In Vitro Maturation and Culture of Human Oocytes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Large Porcine Model of Profound Acute Ischemic Cardiogenic Shock

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Targeted Rhesus immunoglobulin for RhD negative women undergoing an induced abortion: a clinical pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Blood group genotyping of blood donors: validation of a highly accurate routine method

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Lessons learned from the implementation of non-invasive fetal RHD screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

RhD negative pregnant women who carry an RhD positive fetus are at risk of immunization against the D antigen, which may result in hemolytic disease of the fetus and the newborn. Predicting the fetal RhD status by noninvasive antenatal screening for the fetal RhD gene (RHD) can guide targeted use of antenatal anti-D prophylaxis.Cell-free fetal DNA is extracted from maternal plasma from RhD negative pregnant women at a gestational age of 25 weeks. A real-time PCR-based detection of two RHD exons enables reliable prediction of the fetal RhD status to determine the administration of antenatal prophylaxis, as well as postnatal prophylaxis.

OriginalsprogEngelsk
TidsskriftMethods in molecular biology (Clifton, N.J.)
Vol/bind1885
Sider (fra-til)347-359
Antal sider13
ISSN1064-3745
DOI
StatusUdgivet - 2019

ID: 57849819